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Objective: To evaluate recreational and medical can-
nabis use in individuals with traumatic spinal cord 
injury, including reasons and predictors for use, per-
ceived benefits and negative consequences.
Design: Cross-sectional survey in Denmark.
Methods: A 35-item questionnaire was sent to 1,101 
patients with spinal cord injury who had been in con-
tact with a rehabilitation centre between 1990 and 
2012.
Results: A total of 537 participants completed the 
questionnaire. Of these, 36% had tried cannabis at 
least once and 9% were current users. Of current 
users, 79% had started to use cannabis before their 
spinal cord injury. The main reason for use was plea-
sure, but 65% used cannabis partly for spinal cord 
injury-related consequences and 59% reported at 
least good effect on pain and spasticity. Negative 
consequences of use were primarily inertia and fee-
ling quiet/subdued. Lower age, living in rural areas/
larger cities, tobacco-smoking, high alcohol intake 
and higher muscle stiffness were significantly as-
sociated with cannabis use. Those who had never 
tried cannabis reported that they would mainly use 
cannabis to alleviate pain and spasticity if it were 
legalized.
Conclusion: Cannabis use is more frequent among 
individuals with spinal cord injury in Denmark than 
among the general population. High muscle stiffness 
and various demographic characteristics (lower age, 
living in rural areas/larger cities, tobacco-smoking 
and high alcohol intake) were associated with can-
nabis use. Most participants had started using can-
nabis before their spinal cord injury. There was 
considerable overlap between recreational and disa-
bility-related use.
Key words: spinal cord injury; traumatic; pain; spasticity; 
cannabis; survey.
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Pain and spasticity are common sequelae of spinal cord injury (SCI), with approximately 80% of in-
dividuals with SCI reporting pain and 70% reporting 
spasticity. Both conditions are often insufficiently 
treated and have a negative impact on patients’ quality 
of life (1–3). 
Cannabis is widely used for psychoactive and medi-
cal purposes because of its content of bioactive cannabi-
noids. The cannabinoid system plays a role in inhibiting 
synaptic transmission and controlling synaptic plasticity 
in pain and motor pathways through activation of the 
G-protein-coupled cannabinoid receptors CB1 and 
CB2. The 2 best-studied constituents of cannabis are 
Δ9-Tetrahydrocannabinol (THC), which binds prefe-
rentially at CB1 receptors and has high psychoactive 
effects and abuse potential, and cannabidiol (CBD), 
which has limited psychoactive effects (4). Individuals 
with SCI have, in several studies, reported that canna-
bis use relieves their pain and spasticity (5, 6), but our 
knowledge of the extent and characteristics of cannabis 
use in the SCI population in Denmark is inadequate. 
A number of studies in the general population and spe-
cific disease populations have found that anxiety, stress, 
pain, depression, nausea, appetite stimulation, sleep 
improvement, alleviation of muscle spasms, spasticity, 
facilitation of pleasure and partying are commonly given 
as reasons for using cannabis (7–10). Cannabis users 
more often smoked and drank alcohol than non-users 
and had more often tried cannabis in early adolescence, 
were younger, more often males and had lower income 
and lower socioeconomic status than non-users (11, 
12). In individuals with HIV, lower income, tobacco 
smoking, ecstasy use and living in a rural areas were 
associated with cannabis use (9), while in a study of 
multiple sclerosis, tobacco-smoking, greater disability 
according to patients’ self-evaluation (especially in the 
lower limbs), and marriage or being in a stable relation-
ship were associated with cannabis use (7). 
The main aim of the current study was to evaluate 
the use of recreational and medical cannabis in a na-
tionwide population with traumatic SCI in Denmark, 
including predictors and reasons for use, benefits and 
negative consequences. A secondary aim of this cross-
sectional survey in Denmark was to determine the 
prevalence, severity and impact of pain and spasticity 
in this population. These results were reported earlier 
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Statistical analysis
Data were described as mean (SD) or median (range) or frequen-
cy and percentages. Normality was checked using histograms 
and quantile-quantile (Q-Q) plots. Numerical data were analysed 
using unpaired t-test or Mann-Whitney U test. Categorical vari-
ables were analysed using χ2 test or Fisher’s exact test. Variables 
in the univariate analyses with associations with current cannabis 
that had a p-value < 0.05 were included in a logistic regression 
model. A p-value < 0.05 was considered statistically significant. 
The level of missing data for different variables was less than 
2.4%, and this was shown in the results tables. Missing data were 
not replaced. Statistical analysis was performed using STATA 
release 12 (StataCorp, College Station, TX, USA).
Ethics statement
The authors certify that all applicable institutional and governme-
ntal regulations concerning the ethical use of human volunteers 
were followed during the course of this research. The study was 
approved by the Danish Data Protection Agency, Copenhagen, 
Denmark (no. 1-16-02-210-14) and Danish Health and Medicines 
Authority, Copenhagen, Denmark (no. 3-3013-621/1).
RESULTS
Participants
In the period 1990–2012, 1,371 individuals aged 18 
years or over with an acquired traumatic SCI had been 
in contact with at least one of the two rehabilitation 
centres in Denmark. A total of 1,101 individuals were 
sent the questionnaire (Fig. 1). The response rate was 
49.4% (544 individuals), of whom 196 responded via 
the web-based and 348 via the paper-based questionn-
aire. Of the returned questionnaires, 7 were incomplete 
with no information on cannabis use, and were the-
refore excluded. Consequently, questionnaires from 
537 individuals were included and analysed (Fig. 1).
METHODS
Study design
This was an anonymous nationwide questionnaire study. Entry 
criteria were: age 18 years or over, acquired traumatic SCI 
and contact with one of the two SCI rehabilitation centres in 
Denmark (Spinal Cord Injury Centre of Western Denmark in 
Viborg or Clinic for Spinal Cord Injuries in Hornbaek) from 
1990 to 2012.The questionnaire was sent by post in January–
April 2015. Participants had the option to complete either a 
web-based questionnaire (via survey-xact.dk) or a paper-based 
questionnaire. Cannabis consumption is illegal in Denmark, 
therefore all replies were anonymous and no reminders were 
sent out to non-responders. 
Questionnaire
Questionnaire data included demographic variables (age, sex, 
marital status, education level, region of residence and popu-
lation density), labour force information (occupation, labour 
market affiliation, income) and lifestyle behaviours and habits 
(alcohol consumption, tobacco-smoking) (14). Information 
about the participants’ spinal cord injuries included cause, 
year of injury, whether the participant was tetraplegic (arms, 
body and legs affected) or paraplegic (body and legs affected), 
had a complete (no sensation or voluntary muscular function 
below injury level) or incomplete (some sensation and mus-
cular function below the injury level) injury (15) and to what 
level daily life was limited due to the SCI (“not at all”, “little”, 
“moderate” and “much”). 
Participants were asked if they had experienced continuous 
or daily recurring pain for more than 3 months. If participants 
answered “yes” they were considered to have chronic pain 
and they were asked to complete the International SCI Pain 
Basic Data Set (16), which includes rating mean pain intensity 
over the past 7 days on a 0–10 numeric rating scale (NRS). 
Pain treatment was recorded. Participants were also asked if 
they had experienced spasticity (muscle stiffness or spasms). 
Intensity of muscle stiffness was rated on an NRS (0–10) 
and the Penn Spasm Frequency Scale (17) was completed. 
Spasticity treatment was determined using a list of treatment 
options. Quality of life was assessed using the 
International SCI Quality of Life Basic Data 
Set (18), whereby participants estimated how 
satisfied they had been with their life situation 
and physical and mental health in the past 
week using an NRS (0–10). Participants also 
rated sleep disturbances during the past week 
on an NRS (0–10).
Participants were asked if they had tried 
cannabis at any time in their lives. If not, they 
were asked if they would try it if it were legal 
and for what reason. Those who had tried or 
used cannabis one or more times were asked 
about their age of debut. They were also asked 
if they had tried it before and/or after their SCI, 
how many times they had tried or used it, in 
what form and the reason for using cannabis. 
Participants who had used cannabis within the 
last 2 years were defined as “current” cannabis 
users and were given further questions about 
frequency, quantity, cause and effect of their 
cannabis consumption, as well as the extent 
of negative consequences (9). Fig. 1. Study flow chart. *No information on cannabis use.
Assessed for eligibility 
(n=1,371) 




Response rate =49.4% 
Questionnaires analysed 
(n=537) 
Not eligible (n=270) 
• current address abroad (n=45) 
• unknown Central Person Registry (n=69) 
• unknown address (n=139) 
• double entry (listed at both centres) (n=17) 
Questionnaires not returned (n=557) 
Questionnaires incomplete (n=7)* 
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Demographics and clinical characteristics
Demographic variables and clinical characteristics of 
study subjects are shown in Table I. Mean age was 
54.6 years (SD 14.6), age range 18–88 years; 77% 
were men, and the majority did not live with any 
children, but were either married or in cohabiting re-
lationship (41%) or alone (35%). The majority lived 
in small- to-medium-sized cities, and 41% stated that 
they had at least a short post-secondary education. 
The majority of participants were non-smokers and 
their alcohol consumption was within the guidelines 
set by the Danish Health and Medicines Authority 
(14 units/week for men and 7 units/week for women). 
The mean time since injury was 18.2 (SD 12.8) years; 
46% of responders were tetraplegic, and 68% had an 
incomplete injury. The most common causes of injury 
were transportation (41%) and falls (30%) (Table I). A 
total of 412 participants (77%) reported that their SCI 
had at least a moderate impact on their everyday life 
(Table I). A total of 390 (73%) participants reported 
chronic pain, in whom the mean intensity (NRS, 0–10) 
was 5.6 (SD 2.3) and 259 (67%) received treatment for 
pain. Spasticity was reported by 378 (71%) and 46% 
of these received treatment for spasticity (Table I).
Cannabis use
Thirty-six percent (195 of 537) of all participants 
had tried cannabis at least once. Of these, 75% (147 
of 195) were former cannabis users and 25% (48 of 
195) current cannabis users (Table I). To be able to 
compare our data with available data on the general 
Danish population the group was subdivided by age. 
Of the 140 participants under the age of 45 years, 75 
(53.6%) had tried cannabis at least once, in contrast to 
120 (30.2%) of the 397 participants who were 45 years 
or older. The mean age for trying cannabis for the first 
time was 20.4 (SD 9.1), range 8–72 years. Comparing 
current with former cannabis users, there was no dif-
ference (p = 0.76). Of the 195 participants who had tried 
cannabis, 52% had used it before, 20% after, and 28% 
both before and after their SCI. In the latter group, 53% 
reported that their consumption had decreased, 15% 
that it had increased, and 32% that it was unchanged 
after their SCI. Of the 48 current cannabis users, 10 
(21%) had tried cannabis after their SCI only. 
Among participants who had tried cannabis (n=195), 
174 (89%) stated that they had tried it for pleasure, 42 
(22%) for medicinal use in relation to their SCI (such as 
pain and spasticity), 8 (4%) for other medical reasons 
(depression, anxiety, stress, anorexia), and 17 (9%) 
gave other reasons (sleep, sex, partying and curiosity). 
Among the 147 former cannabis users, 38 (26%) had 
tried it more than 20 times, 17 (18%) 11–20 times, and 
90 (62%) 10 times or less. Former cannabis users most 
often used hashish, whereas current users also con-
sume a variety of other forms of cannabis, which may 
contain more THC, such as skunk (Fig. 2). Medical 
cannabis  (sativex or dronabinol) was not commonly 
used (4 current and 3 former cannabis users). Of the 







Tried cannabis (n = 195) Not current
cannabis users
(n = 489) p-value
Former cannabis 
users (n = 147)
Current users 
(n = 48)
Age, years, mean (SD), n = 537 54.6 (14.6) 57.8 (14.4) 51.2 (12.8) 42.5 (12.3) 55.8 (14.3) < 0.001 
Sex, male, n (%), n = 537 413 (77) 248 (73) 123 (84) 42 (88) 371 (76) 0.068 
Education, n (%), n = 535 0.008
  Below high-school graduate 99 (19) 68 (20) 22 (15) 9 (19) 90 (18)
  High-school graduate 41 (8) 22 (6) 12 (8) 7 (15) 34 (7)
  Skilled education 154 (29) 110 (32) 35 (24) 9 (19) 145 (30)
  Shorter courses 22 (4) 13 (4) 3 (2) 6 (13) 16 (3)
  Short post-secondary education 57 (11) 34 (10) 17 (12) 6 (13) 51 (10)
  Middle post-secondary education 109 (20) 68 (20) 36 (24) 5 (10) 104 (21)
  Long post-secondary education 53 (10) 25 (7) 22 (15) 6 (13) 47 (10)
Employment, n (%), n = 537 0.68
  Yes, employed full-time 84 (16) 49 (14) 29 (20) 6 (13) 78 (16)
  Yes, employed part-time 103 (19) 62 (18) 33 (22) 8 (17) 95 (19)
  Not employed 350 (65) 231 (68) 85 (58) 34 (71) 316 (65)
Personal income, per year, n (%), n = 536 0.062
  <199,999 DKK 209 (39) 145 (43) 47 (32) 17 (35) 192 (39)
  200,000–399,999 DKK 186 (35) 113 (33) 56 (38) 17 (35) 169 (35)
  400,000–699,999 DKK 77 (14) 47 (14) 27 (18) 3 (6) 74 (15)
  ≥700,000 DKK 19 (4) 10 (3) 7 (5) 2 (4) 17 (3)
  Unknown 45 (8) 26 (8) 10 (7) 9 (19) 36 (7)
Relationship, n (%), n = 534 0.01
  Married/cohabiting living without children 220 (41) 162 (47) 48 (33) 10 (22) 210 (43)
  Married/cohabiting living with children 94 (18) 58 (17) 29 (20) 7 (15) 87 (18)
  Alone living with children 35 (7) 17 (5) 12 (8) 6 (13) 29 (6)

















































Tried cannabis (n = 195)
Not current
cannabis users 
(n = 489) p-value
Former cannabis 
users (n = 147)
Current users 
(n = 48)
  Capital Region of Denmark 149 (28) 75 (22) 55 (37) 19 (40) 130 (27)
  Region Zealand 117 (22) 78 (23) 32 (22) 7 (15) 110 (22)
  Region of Southern Denmark 117 (22) 85 (25) 24 (16) 8 (17) 109 (22)
  Central Denmark Region 98 (18) 63 (18) 25 (17) 10 (21) 88 (18)
  North Denmark Region 56 (10) 41 (12) 11 (7) 4 (8) 52 (11)
Population in their city, n (%), n = 537 0.001
  0–999 81 (15) 58 (17) 20 (14) 3 (6) 78 (16)
  1,000–4,999 96 (18) 71 (21) 23 (16) 2 (4) 94 (19)
  5,000–19,999 102 (19) 64 (19) 28 (19) 10 (21) 92 (19)
  20,000–99,999 148 (28) 95 (28) 38 (26) 15 (31) 133 (27)
  100,000–299,999 29 (5) 16 (5) 9 (6) 4 (8) 25 (5)
  ≥300,000 54 (10) 18 (5) 24 (16) 12 (25) 42 (9)
  Unknown 27 (5) 20 (6) 5 (3) 2 (4) 25 (5)
Tobacco-smoking, n (%), n = 533 < 0.001
  Yes, daily 104 (20) 48 (14) 29 (20) 27 (56) 77 (16)
  Yes, sometimes 30 (6) 13 (4) 11 (7) 6 (13) 24 (5)
  No, but smoked earlier 201 (38) 124 (37) 70 (48) 7 (15) 194 (40)
  Have never smoked 198 (37) 153 (45) 37 (25) 8 (17) 190 (39)
Age started tobacco-smoking, mean (SD), n =132/134 16.9 (6.0) 17.8 (6.8) 16.2 (4.2) 16.1 (6.2) 17.1 (6.0) 0.40
Alcohol consumption, n (%), n =535 0.59
  Yes, daily 73 (14) 44 (13) 21 (14) 8 (17) 65 (13)
  Yes, sometimes 357 (67) 222 (65) 102 (69) 33 (69) 324 (67)
  Never 105 (20) 74 (22) 24 (16) 7 (15) 98 (20)
Alcohol >7 (women) and > 14 (men) units/week, n (%), n =530 74 (14) 36 (11) 24 (16) 14 (30) 60 (12) 0.001
Age started drinking alcohol, mean (SD), n =414/430 16.6 (5.2) 17.5 (6.2) 15.2 (2.2) 15.3 (3.2) 16.8 (5.3) 0.08
Spinal cord injury
Time since injury, years, mean (SD), n =532 18.2 (12.8) 17.9 (13) 20.1 (12.8) 14.2 (10) 18.6 (13) 0.03
Impairment category, n (%), n =535 0.90
 Tetraplegia 244 (46) 149 (44) 73 (50) 22 (46) 222 (46)
 Paraplegia 263 (49) 168 (49) 72 (49) 23 (48) 240 (49)
 Unknown 28 (5) 23 (7) 2 (1) 3 (6) 25 (5)
Completeness, n (%), n =535 0.57
  Complete 165 (31) 105 (31) 42 (29) 18 (38) 147 (30)
  Incomplete 344 (64) 214 (63) 102 (69) 28 (58) 316 (65)
  Unknown 26 (5) 21 (6) 3 (2) 2 (4) 24 (5)
Causality of SCI, n (%), n =534 0.39
  Sports 82 (15) 47 (14) 29 (20) 6 (13) 76 (16)
  Assault 7 (1) 3 (1) 3 (2) 1 (2) 6 (1)
  Transport 219 (41) 116 (34) 79 (54) 24 (50) 195 (40)
  Fall 161 (30) 124 (37) 27 (18) 10 (21) 151 (31)
  Other traumatic cause 65 (12) 49 (14) 9 (6) 7 (15) 58 (12)
SCI impact on everyday life, n (%), n =534 0.63
  Not at all 16 (3) 9 (3) 6 (4) 1 (2) 15 (3)
  Some 106 (20) 66 (19) 27 (18) 13 (27) 93 (19)
  Moderate 186 (35) 119 (35) 52 (35) 15 (31) 171 (35)
  Much 226 (42) 145 (43) 62 (42) 19 (40) 207 (43)
Quality of life, NRS 0–10, mean (SD)
  Satisfaction with life and life situation, n = 532 6.5 (2.5) 6.6 (2.5) 6.4 (2.4) 6.1 (2.8) 6.6 (2.4) 0.17
  Satisfaction with physical health, n = 532 5.5 (2.6) 5.6 (2.6) 5.2 (2.6) 5.4 (2.6) 5.4 (2.6) 0.86
  Satisfaction with mental health, feeling, mood, n = 531 6.7 (2.6) 6.8 (2.6) 6.6 (2.5) 6.1 (2.9) 6.8 (2.6) 0.13
Sleep disturbance, NRS 0–10, median (range), n = 534 5.0 (0–10) 4.0 (0–10) 4.0 (0–10) 6.0 (0–10) 4.0 (0–10) 0.06
Pain, n (%), n = 536 390 (73) 255 (75) 101 (69) 34 (71) 356 (73) 0.75
Pain intensity, NRS 0-10, median (range), n = 524 4.5 (0–10) 5.0 (0–10) 3.0 (0–10) 4.0 (0–10) 5.0 (0–10) 0.71
Drug treatment for pain, n (%), n = 535 259 (48) 171 (50) 68 (46) 20 (42) 239 (49) 0.32
Spasticity, n (%), n = 536 378 (71) 227 (67) 113 (77) 38 (79) 340 (70) 0.17
Muscle stiffness intensity, NRS 0–10, median (range), n = 524 2.0 (0–10) 2.0 (0–10) 2.0 (0–10) 4.0 (0–10) 2.0 (0–10) 0.01
Spasm frequency, n (%), n = 533 0.09
  No spasms 172 (32) 123 (36) 37 (26) 12 (25) 160 (33)
  Mild spasms induced by stimulation 189 (35) 115 (34) 58 (40) 16 (33) 173 (36)
  Infrequent full spasms occurring < 1 per h 111 (21) 69 (20) 33 (23) 9 (19) 102 (21)
  Spasms occurring > 1 per h 42 (8) 24 (7) 9 (6) 9 (19) 33 (7)
  Spasms occurring > 10 times per h 19 (4) 9 (3) 8 (6) 2 (4) 17 (4)
Drug treatment for spasticity, n (%), n = 535 172 (32) 109 (32) 42 (29) 21 (44) 151 (31) 0.21
NRS: numeric rating scale; SD: standard deviation; DKK: Danish krone.
*Current (n = 48) vs non-current (n = 489) users. Significant values are shown in bold. Tried cannabis: have tried cannabis at least once in their lifetime; Former 
cannabis users: those who have tried cannabis, but have not used cannabis within the last 2 years; Current users: those who have used cannabis within the last 
2 years; Not current cannabis users: former cannabis users and never used cannabis.
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342 participants who had never tried cannabis, 69 
(20%) responded that they would try it if it were legal 
and they reported pain, spasticity and sleep disturbance 
as the most common reasons (Fig. 3a).
Current cannabis users
Further details were obtained for the 48 current can-
nabis users, i.e. the participants who had used cannabis 
within the past 2 years. Thirty-one (65%) were under 
45 years old. Twenty-two percent of the participants 
under 45 years of age and 4% of participants 45 years 
of age or older were current cannabis users. The mean 
age of current users under 45 years of age was 34.9 
(SD 7.2) years. Among the 48 current users, 14 (29%) 
reported daily use, 12 (25%) used at least once per 
week, 7 (15%) at least once per month, 10 (21%) at 
least once per year, and 5 (10%) less than once per year. 
Thirty-eight (79%) participants had tried cannabis more 
than 20 times, 3 (6%) between 11 and 20 times and 7 
(15%) l0 times or less. Among current cannabis users, 
39 (81%) stated they had tried it for pleasure, 31 (65%) 
for medicinal use in relation to their SCI, 7 (15%) for 
other medical reasons, and 7 (15%) gave other reasons. 
Ten percent (5/48) of current cannabis users reported 
their use of cannabis for no other reason than for the 
secondary complications due to their SCI. Of the 31 
participants who also used it for medical reasons in 
relation to their SCI, 8 had started using cannabis after 
their SCI. Among the 26 participants who knew their 
level of consumption of cannabis, the mean intake in the 
previous 4 weeks was 13.8 (SD 25.1) g and the mean 
costs during the same period was 514.4 (SD 868.9) 
DKK (approximately 69 (SD 116.5) Euro). The most 
frequently reported reasons for using cannabis were 
pleasure, followed by pain, partying and spasticity 
(Fig. 3b). Most participants reported a good to very 
good effect (Fig. 3b). For pain (29/48), 10 (35%) had a 
good and 7 (24%) a very good effect, and for spasticity 
(22/48), 7 (32%) had a good and 6 (27%) a very good 
effect. The 4 individuals who used medical cannabis 
(dronabinol and sativex) reported none or some effect 
on pain and spasticity. Of current cannabis users 8.3 
% (4 of 48) used medical cannabis. Current cannabis 
users took paracetamol less often than participants who 
were not current cannabis users (p = 0.030), while there 
was no significant difference between current and not-
current cannabis users in terms of other treatments for 
pain or spasticity (p > 0.05).
Negative consequences of cannabis use included 
inertia, feeling quiet/subdued, absentmindedness 
and risky behaviour, which were most often rated as 
slightly to moderately serious (Fig. 4).
Fig. 2. Type of cannabis used by current (have used cannabis within 
the past 2 years, n = 48) and former (have not used cannabis within the 
past 2 years, n = 147) cannabis users *p <0.05; **p <0.01. 
Fig. 3. (A) Reasons why participants who had never tried cannabis would try it if cannabis were legal (n = 69). (B) Reasons for cannabis use as well 
as experienced effect among current cannabis users (n = 48). *Other reasons included: (a) headache, sex problems, constipation, as treatment, 
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tic regression model. The overall model was significant 
(p < 0.001) with an overall classification accuracy of 
93%. Lower age, a city population of 5,000–19,999 
and > 100,000, tobacco-smoking, alcohol consumption 
exceeding recommended units per week, and higher 
muscle stiffness scores were significantly associated 
with cannabis use (Table II).
DISCUSSION
This nationwide questionnaire study of 537 individuals 
with SCI found that 36% had tried cannabis at least 
once. Forty-eight participants (9%) had used cannabis 
within the past 2 years and were considered current 
users, which is lower than found in 2 previous studies 
in other disease populations. Harris et al. (9), a cross-
sectional survey in Canada of 256 patients, found that 
38.5% of participants with HIV/AIDS were current 
cannabis users, which was a 3.5-fold higher prevalence 
Associations with current cannabis use
Significant variables identified through the univariate 
analyses in Table I were examined further using a logis-
Table II. Demographic and clinical characteristics associated with cannabis use. Variables in logistic regression model
Predictors Odds ratio 95% CI SE z p-value
Age group
  < 30 years 16.0 3.2–79.2 13.1 3.39 0.001
  31–45 years 13.2 3.6–48.3 8.7 3.89 < 0.001
  46–60 years 1.0
  > 61 years 0.5 0.1–2.0 0.3 –1.02 0.307
Education
  Below high-school graduate 1.0
  High-school graduate 0.6 0.1–2.7 0.5 –0.69 0.492
  Skilled education 0.5 0.1–1.9 0.3 –0.98 0.325
  Shorter courses 2.3 0.3–18.4 2.4 0.79 0.427
  Short post-secondary education 0.7 0.2–3.2 0.5 –0.46 0.646
  Middle post-secondary education 0.5 0.1–2.3 0.4 –0.89 0.375
  Long post-secondary education 0.8 0.2–4.5 0.7 –0.20 0.840
Relationship
  Married/cohabiting living without children 1.2 0.4–4.3 0.8 0.33 0.739
  Married/cohabiting living with children 0.4 0.1–1.4 0.3 –1.41 0.159
  Alone and living with children 1.9 0.5–8.0 1.4 0.91 0.362
  Alone and living without children 1.0
City population
  0–999 1.0
  1,000–4,999 0.1 0–2.6 0.2 –1.33 0.184
  5,000–19,999 6.8 1.0–44.6 6.5 1.99 0.047
  20,000–99,999 4.3 0.7–27.4 4.1 1.54 0.123
  100,000–299,999 10.7 1.3–90.3 11.6 2.18 0.029
  ≥ 300,000 30.6 3.9–239 32.1 3.26 0.001
  Unknown 1.2 0.1–14.9 1.6 0.16 0.874
Tobacco-smoking
  Yes, daily 20.2 5.9–70.0 12.8 4.75 < 0.001
  Yes, sometimes 8.0 1.6–40.6 6.6 2.50 0.012
  Have never smoked 1.0
  No, but smoked earlier 2.5 0.7–9.5 1.7 1.39 0.163
Alcohol consumption (n)
  Consumption (men ≤ 14 units/women ≤ 7 units) 1.0
  Consumption (men > 14 units/women > 7 units) 3.1 1.0–9.6 1.8 1.96 0.049
Time since injury, years
  <10 1.3 0.5–3.5 0.7 0.43 0.669
  11–20 1.0
  >21 1.6 0.5–5.2 1.0 0.75 0.456
Muscle stiffness (NRS 0–10)
  0–3 1.0
  4–6 1.2 0.5–3.3 0.6 0.44 0.657
  7–10 4.0 1.2–14.1 2.6 2.19 0.029
Significant values are shown in bold. SE: standard error; CI: confidence interval.
Fig. 4. Negative consequences of cannabis use and the seriousness of 
these consequences reported by current cannabis users (n = 48). *Other 
consequences included loss of mobility, fines and insecure transfer (e.g. 
from wheelchair to bed).
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than in the general Canadian population. In a multiple 
sclerosis study in the UK (7), 18% of 254 responders 
were current cannabis users. Medical use of Cannabis is 
legal in Canada, but not in the UK or Denmark, which 
may influence the number of individuals using cannabis. 
The Danish Health and Medicines Authority provides 
national data for the use of cannabis in individuals under 
45 years of age (n = 5,748 in the year 2010)(19). In our 
study, 54% (75/140) of participants under 45 years of 
age had tried cannabis at least once, and 22% (31/140) 
had used cannabis within the past 2 years compared 
with the general Danish population, of whom 41.5% of 
individuals under the age of 45 years had tried cannabis 
at least once and 8.9% had used cannabis within the past 
year, and 78% of current users were between 16 and 
24 years of age (19). Comparing our study population 
(n =  140) with the Danish general population (n = 5,748) 
under the age of 45 years, suggests that our population 
used cannabis more often than the Danish general po-
pulation. A possible reason for the higher use among 
individuals with SCI may be that cannabis use increases 
risky behaviour and users therefore have a greater risk 
of accidents and thus SCI. This may be supported by 
the fact that 38 of the 48 current cannabis users started 
their cannabis use before their SCI. Increased inciden-
ces of accidents were seen in the USA when cannabis 
was legalized and became more accessible to a larger 
population (20). Another possible explanation is that 
persons using cannabis are risk prone, i.e. are more 
likely to drink alcohol, use cannabis and engage in 
activities with a risk of accidents (21). It is also pos-
sible that living with SCI and the consequent secondary 
complications may lead to increased cannabis use, since 
31 of the 48 current users reported that they used can-
nabis partly for relief of secondary complications due 
to their SCI, although only 8 of these had started using 
cannabis after their injury. 
In our study, pleasure, followed closely by pain, 
partying and spasticity, were the most frequent reasons 
for cannabis use. Thirty-one (65%) of current cannabis 
users, corresponding to 5.8% of the whole sample, 
reported that they used cannabis partly to relieve SCI-
related symptoms, while 81% reported that they had 
tried it for pleasure. Ten percent used it exclusively for 
SCI-related symptoms. In comparison, for individuals 
with HIV/AIDS, 22% of cannabis users and 8.4% of 
a total study population of 226 reported medicinal 
cannabis use (9). However, 81% of all cannabis users 
reported medically related symptoms as reasons for use 
in addition to recreational use, which was reported by 
98%, Only 2.3% of current users reported medicinal use 
only (9). Thus, in both populations there is considerable 
overlap between medical and recreational cannabis use. 
In studies of multiple sclerosis, 18% (46/254) of the 
total population reported current use of cannabis (7), 
and 12% (31/254) and 10% (43/420) reported using 
cannabis to relieve disease-associated symptoms (7, 
10). The slightly higher percentage of current users 
among individuals with multiple sclerosis may partly 
be because this population is more aware of cannabis 
being potentially useful to alleviate their symptoms (10). 
Among those who had never tried cannabis, 20% 
reported that they would try cannabis if it was legal, 
and the majority of these would use cannabis for their 
pain, spasticity and sleep disturbance. A previous study 
of multiple sclerosis (n = 254) in UK found that over 
70% of individuals who had never used cannabis would 
try it if it were available on prescription (7). The same 
reasons were also commonly reported by current users, 
although in this group, pleasure and partying were other 
common reasons. Most current users reported at least 
some effect on pain, spasticity and sleep disturbance. 
Less effect was reported by the 4 participants who used 
medical cannabis. The effect of marijuana on pain and 
spasticity following SCI was suggested already in 1974 
(22), and in a more recent questionnaire study from the 
US, marijuana was reported as an alternative pain tre-
atment by 32% and, of all treatments, was rated as the 
one that gave the greatest pain relief (5). Other studies 
have reported the use of cannabis in pain and spasticity 
(6, 23). Cannabinoid medications have been developed 
and are now used in the treatment of pain and spasticity. 
These include dronabinol and nabilone, which are synt-
hetic THCs, nabiximols (sativex), which is an oromuco-
sally delivered spray containing extracts of the cannabis 
plant. Two trials failed to find effect of dronabinol or 
sativex for SCI neuropathic pain (24) (Clinicaltrials.
gov, NCT01606202). Except for the use of smoked or 
inhaled cannabis, which in a few short-term trials has 
shown efficacy on different neuropathic pain conditions, 
not including SCI neuropathic pain (25, 26), randomi-
zed controlled trials have shown conflicting results for 
neuropathic pain (27). Recent recommendations from 
the Neuropathic Pain Special Interest Group of the 
International Association for the Study of Pain (27) 
include a weak recommendation against the use of can-
nabinoids for neuropathic pain, due to negative results, 
side-effects, issues of misuse and abuse and possible 
long-term risks of psychosis and cognitive impairment, 
in particular in susceptible individuals (28, 29), although 
this is still debated (30). Few studies have examined the 
effect of medical cannabis on SCI-related spasticity. In 
a single case trial, there was an effect of delta-9-THC 
(31), whereas an unpublished trial showed no effect 
of sativex on SCI-related spasticity (Clinicaltrials.gov, 
NCT01606202). Also, for spasticity due to multiple 
sclerosis, the results are conflicting (32). In Denmark, 
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risk of type 1 error. The low response rate may have 
been due to cannabis use being illegal in Denmark, and 
to the fact that it was not possible to send out reminders 
as the response was anonymous. 
We were not authorized to access information held in 
the medical records by the Danish Health and Medicines 
Authority, therefore it is not known whether our sample 
population is representative of the whole group who 
received the questionnaire. However, epidemiological 
studies suggest that our sample is representative of the 
population with traumatic SCI in Denmark. A recent 
Danish epidemiological study for the period 1990–2012 
found the median age at injury to be 35 years, with a 
predominance of men (81.9%) (40). By comparison, our 
study showed a prevalence of 77% (413/537) was found 
in men, with a median age at injury of 33 years. Pre-
vious studies (Bjørnshave et al. 2015 (n = 691) and  Lee 
et al. 2014 (9.2 per million in Denmark)) have shown 
that transportation (47%) and falls (26%) are the main 
causes of SCI in Denmark (40, 41), which is similar to 
the results of our study. The distribution of tetraplegia 
(51%) and paraplegia (49%) among individuals with 
SCI in Denmark (41) is also consistent with our results. 
Conclusion
The current study found the prevalence of current 
cannabis users among persons with traumatic SCI in 
Denmark to be slightly higher than previously reported 
in the Danish general population. This may be due to 
an increased risk of accidents among cannabis users. 
Most participants started using cannabis before their 
SCI and used it for recreational purposes, but some 
also reported some effect on pain and spasticity. Ap-
proximately 20% of those who had never tried cannabis 
stated that, if cannabis use were legal, they would try 
it in order to alleviate symptoms due to SCI. Cannabis 
use was associated with lower age, living in rural areas 
and larger cities, tobacco-smoking, high alcohol intake 
and higher muscle stiffness. There is currently limited 
evidence for the use of medical cannabis for SCI-
related pain and spasticity, and there are concerns about 
side-effects and long-term risks. Further research into 
cannabinoid treatments and the development of can-
nabinoid drugs with fewer psychological side-effects, 
such as CB2 receptors agonists, palmitoylethanolamide 
analogues and endocannabinoid-degrading-enzyme 
inhibitors, is needed.
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but with specific requirements for reimbursement, and 
it is illegal to drive while using medical cannabinoids, 
which may explain the low number of individuals with 
SCI using medical cannabis in this study. 
The mean age of debut for cannabis use in our po-
pulation was 20 years, which is consistent with a debut 
in the Danish general population of 16–24 years (33), 
but lower than the 23.3 years reported in the study in 
an HIV/AIDS population from Canada (9). 
Participants in the current study reported a mean 
consumption of cannabis of 13.8 g (SD 25.1 g) per 4 
weeks, but the amount of cannabis ranged from 0 to 
100 g per 4 weeks. Participants spent between 0 and 
3,000 DKK per 4 weeks, with a mean amount of 514.4 
DKK (SD 868.9) per 4 weeks. A recent study looking 
at the correlation between cannabis use and HIV/AIDS 
showed almost the same consumption of cannabis 
(18.3 g) and cost (USD 105.15) per month (9), while 
an earlier study of HIV showed a considerably higher 
consumption of cannabis, up to a mean of 66 g and 
USD 243 per month on average (34). 
Current cannabis users took paracetamol less often 
than participants who were not current cannabis users. 
This is of interest since paracetamol has been shown to 
inhibit cellular synaptic space reuptake of anandamide 
and thus have cannabinoid-like analgesic effects (35, 
36). A synergistic interaction effect between cannabi-
noids and paracetamol has also been suggested (37), 
which is of interest for future studies.
Inertia, feeling quiet/subdued, absentmindedness 
and risky behaviour were described by participants as 
negative consequences and were reported as slightly 
to moderately serious. Since this was a cross-sectional 
survey, we were not able to examine the long-term 
effect. Several studies have shown that there may be 
an increased risk of developing both psychotic and 
cognitive dysfunction (4, 25, 38, 39), and both short- 
and long-term effects and the potential for abuse and 
addiction (39) should be considered if cannabis were 
to be offered as treatment for pain or spasticity.
Factors associated with cannabis use in our SCI 
population were lower age, the number of residents in 
the city where the participants lived (both smaller and 
larger cities), tobacco-smoking (both daily and periodi-
cally), higher alcohol consumption and higher muscle 
stiffness score (NRS =7–10). This is in agreement with 
previous studies (7, 9, 11, 12). Pain and severity of the 
SCI were not found to predict current cannabis use.
Study limitations
This was a cross-sectional study; therefore it was only 
possible to examine the causal relation between can-
nabis use and the consequences of a SCI. The response 
rate of 49% is relatively low, which could induce the 
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